Tero Aittokallio
PhD
teanai@utu.fi Tykistökatu 6 A Turku ORCID-tunniste: https://orcid.org/orcid.org/0000-0002-0886-9769 |
Tero Aittokallio received his PhD in Applied Mathematics from the University of Turku in 2001, under the supervision of Prof. Mats Gyllenberg. He then did his post-doctoral training in the Systems Biology Lab at the Institut Pasteur (2006-2007), with Dr. Benno Schwikowski, where he focused on network biology applications using high-throughput experimental assays and network analysis tools such as Cytoscape. In 2007, Dr. Aittokallio launched his independent career as a principal investigator in the Turku Biomathematics Research Group, where he received a five-year appointment as an Academy of Finland Research Fellow (2007-2012). Tero Aittokallio joined Institute for Molecular Medicine Finland (FIMM) as EMBL Group Leader in the fall of 2011, and was selected as Professor of Statistics and Applied Mathematics at University of Turku in 2015.
Aittokallio's research group focuses on developing and applying integrated computational-experimental approaches to tackle biomedical questions, such as how genes function as interaction networks to carry out and regulate cellular processes, how alterations in these networks contribute to complex traits, such as human diseases, and where and how in the disease network one should target to optimally inhibit the disease phenotypes, such as tumor growth.
Computational statistics.
Scientific computing.
- Antiandrogens Reduce Intratumoral Androgen Concentrations and Induce Androgen Receptor Expression in Castration-Resistant Prostate Cancer Xenografts (2018)
- American Journal of Pathology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling (2018)
- Leukemia
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Drug-sensitivity screening and genomic characterization of 45 hpV-negative head and neck carcinoma cell lines for novel biomarkers of drug efficacy (2018)
- Molecular Cancer Therapeutics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Drug Target Commons 2.0: a community platform for systematic analysis of drug target interaction profiles (2018)
- Database: The Journal of Biological Databases and Curation
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Drug Target Commons: A Community Effort to Build a Consensus Knowledge Base for Drug-Target Interactions (2018)
- Cell Chemical Biology
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - ePCR: an R-package for survival and time-to-event prediction in advanced prostate cancer, applied to real-world patient cohorts (2018)
- Bioinformatics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Global proteomics profiling improves drug sensitivity prediction: results from a multi-omics, pan-cancer modeling approach (2018)
- Bioinformatics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML (2018)
- Leukemia
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä ) - Improving the efficacy-safety balance of polypharmacology in multi-target drug discovery (2018)
- Expert Opinion on Drug Discovery
(A2 Vertaisarvioitu katsausartikkeli tieteellisessä lehdessä) - Learning with multiple pairwise kernels for drug bioactivity prediction (2018)
- Bioinformatics
(A1 Vertaisarvioitu alkuperäisartikkeli tieteellisessä lehdessä )



